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Abstract
Marijuana (MJ) remains the most widely used illicit drug of abuse, and accordingly, is associated
with adverse effects on mental and physical health, and neurocognitive decline. Studies
investigating the neurobiology of underlying MJ effects have demonstrated structural and
functional alterations in brain areas that contain moderate to high concentrations of cannabinoid
(CB1) receptors and that are implicated in MJ-related cognitive decrements. Proton magnetic
resonance spectroscopy (1H MRS), a non-invasive imaging technique used to assess
neurochemistry, has been widely applied to probe a variety of substance-abusing populations. To
date, however, there is a relative paucity of MRS published studies characterizing changes in
neurometabolite concentrations in MJ users. Thus, the current review provides a summary of data
from the eight existing MRS studies of MJ use in adolescents and adults, as well as interpretations
and implications of study findings. Future MRS studies that address additional factors such as sex
differences, onset and duration of use, abstinence and age, are warranted, and would lead to a
more thorough characterization of potential neurochemical correlates of chronic MJ use, which
would fill critical gaps in the existing literature.
Keywords
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Introduction
Marijuana (MJ) research continues to be a major area of investigation, since it remains the
most widely used illicit drug of abuse in the United States [1]. Frequent long-term MJ use
can have serious adverse effects on mental and physical health, as well as work
performance, family and school interactions [2]. According to the 2011 Monitoring the
Future study, daily MJ use is on the rise, with approximately one in fifteen high school
seniors reporting current daily or near-daily MJ use [3]. It is not surprising that MJ use has
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tbeen increasing among teens, as perceived risks associated with MJ use have been falling
over the past five years, as well as a decline in disapproval of using MJ [3]. The availability
of MJ and early age of onset of use has been shown to be highly predictive of MJ use
initiation, frequency of use, and MJ dependence [4]. Given that adolescence is a
developmental period characterized by rapid functional and structural brain changes,
identifying neurodevelopmental vulnerabilities associated with early and escalating MJ use
during adolescence and the enduring effects of continued heavy use into adulthood, are
critical [5].
Delta-9-tetrahydrocannabinol (Δ9-THC) is the main psychoactive component of MJ, which
acts on cannabinoid (CB1) receptors that are densely distributed within brain networks
critical for learning, memory, attention, cognitive processing, and motor control [6], Brain
regions within these networks that contain moderate to high concentrations of CB1 binding
sites include the hippocampus, frontal cortex, inferior temporal gyrus and occipito-temporal
gyrus, amygdala, thalamus, cerebellum, and basal ganglia [6–8]. Consistent with the known
anatomical distribution of CB1 receptors, studies have shown corresponding MJ-related
functional and neurobiological alterations in these brain regions. Accordingly, a number of
empirical neuropsychological studies have shown that chronic MJ use negatively impacts
attention, frontal executive function, emotional processing, motor skills, and memory, in
adolescent [9–11] and adult MJ users [12–16]. While a meta-analytic study failed to report
substantial long-term neurocognitive deficits associated with MJ use in adults, notable
deficits have been reported in the domains of learning and memory [17]. Impairments in
cognitive processing measured across multiple cognitive domains may reflect the
consequences of MJ-related neurobiological alterations and/or compensatory reorganization
of brain structure and function.
Magnetic resonance imaging (MRI) methods, including diffusion tensor imaging (DTI),
have been utilized to investigate the effects of MJ on brain structure [18,21]. Findings have
revealed reductions in frontal region fractional anisotropy in long-term MJ users, indicating
compromised white matter (WM) fiber bundle integrity, as well as impaired axonal fiber
connectivity in the hippocampal fornix and splenium of the corpus callosum, indicating
micro structural disturbances to WM fiber trajectories [18,22]. Persistent short-term MJ use
during critical neurodevelopmental periods interferes with typical maturation, as adolescent
MJ users have shown altered frontal region and insula cortical thickness, reflective of
potentially aberrant gray matter (GM) development or maturation [21].
Functional magnetic resonance imaging (fMRI) has been widely used for studying
alterations in functional brain activation related to MJ use during the performance of
cognitive challenge tasks [23–27], A recent comprehensive review of fMRI studies is
available from Batalla et al., providing a detailed overview of neuroimaging studies of
chronic effects of MJ use on brain structure and function [28]. Cerebral blood volume
(CBV) studies have also been conducted to investigate MJ effects on cerebral
hemodynamics, with dynamic susceptibility contrast magnetic resonance imaging (DSC
MRI) demonstrating that while CBV levels begin to normalize with continued abstinence
from MJ, specifically in frontal areas, other temporal and cerebellar brain regions show
slower CBV decreases after the cessation of active use [29,30],
Proton magnetic resonance spectroscopy (1H MRS) is another type of non-invasive imaging
technique that has been applied, using single voxel or multiple voxel (magnetic resonance
spectroscopic Imaging, MRSI) acquisition schemes, to characterize alterations in
neurometabolites that reflect cellular health and bioenergetics [31]. There is a paucity of
studies, however, utilizing MRS to investigate the influence of chronic MJ use on brain
chemistry [32,33]. As illustrated in Figure 1, in vivo 1H MRS permits the ability to detect
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tand quantify cerebral metabolites including N-acetyl-aspartate (NAA), myo-inositol (mI),
creatine (Cr), cytosolic choline (Cho), and glutamate (Glu). NAA contributes the largest
signal, second to unsupressed water, in the proton spectrum, and is found primarily in
neurons [34,35]. Though a topic of much debate, NAA has generally been regarded as a
biomarker indicating neuronal viability [34]. Total Cr (tCr; creatine plus phosphocreatine)
plays a major role in energy metabolism in brain, acting both as an energy buffer by
maintaining constant brain adenosine triphosphate (ATP) levels through the creatine kinase
reaction and by distributing energy (via mitochondria) within the brain [36,37]. A number of
resonances contribute to the Cho signal (i.e., choline-containing compounds including free
choline, glycerolphosphocholine and phosphocholine (GPC and PC, respectively), with
these compounds being involved in pathways of cellular membrane synthesis and
degradation [38]. As a marker of astroglial function, mI actively contributes to cell volume
regulation and neuronal energy utilization [39,40]. Finally, Glu is a major excitatory
neurotransmitter found in all brain cell types, with the highest concentration generally being
found in neurons, or GM tissue.
Characterizing changes in neurometabolite concentrations in areas known to be affected
structurally and functionally by chronic MJ use could potentially provide a neurochemical
context for these alterations and further substantiate the growing evidence in the field of
MJ’s neurobiological and cognitive consequences. Despite the wide application of MRS to
study drug effects on brain chemistry, particularly in studies of alcohol abuse and
dependence, only eight papers have been published to date that have empirically examined
MJ effects on brain chemistry using MRS [41,42]. To this end, the current review focuses on
the available MRS studies of MJ use in adults, as well as in adolescents. A general
discussion is provided for the overall findings from each study, along with implications and
future directions for imaging research on MJ abuse in adolescents and adults.
Method
Electronic searches were performed using PubMed and Embase to identify published MRS
studies using the following key words: ‘marijuana’; ‘cannabis’; in combination with ‘MRS’;
‘MRSI’; or ‘proton MRS’. Methods that utilized other neuroimaging modalities such as
computerized tomography (CT), positron emission tomography (PET), structural magnetic
resonance imaging (MRI), diffusion tensor imaging (DTI), functional magnetic resonance
imaging (fMRI), cerebral blood flow (CBF) or cerebral blood volume (CBV) were not
included in the electronic search.
Results
The available eight studies utilizing MRS to investigate alterations in neurochemistry
associated with MJ use are detailed in table 1 and study findings, stratified by adult or
adolescent populations, are summarized below.
To date, five MRS studies investigating MJ effects in adult populations have been published.
Chang et al. reported lower NAA, ml, Cho, and Glu in the basal ganglia, but elevated
thalamic Cr in HIV-negative chronic MJ users [43]. Notably, NAA differences were
observed regardless of HIV status, a finding that did not survive post hoc comparisons, and
was not observed in the MJ-only group. Metabolite alterations were observed in the absence
of neuropsychological performance deficits. In addition, increased frontal WM Glu was
associated with history of MJ use in the HIV-positive MJ users, indicating that length of use
significantly predicts magnitude of metabolite alterations [43]. In a MRS study by Hermann
and colleagues, lower NAA/tCr ratios were observed in the dorsolateral prefrontal cortex
(DLPFC) of recreational MJ users [44]. Cowan et al. based on previous evidence that the
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tneuronal marker NAA and the glial marker mI are altered in ecstasy users, examined the
influence of lifetime cannabis use in combination with recreational ecstasy use [45]. Lower
NAA/Cr levels were evident in Brodmann area (BA) 45 in the frontal lobe, the inferior
frontal gyrus region associated with verbal memory processing. The observed metabolite
alterations were not observed in BA 18 (secondary visual cortex) or BA 21 (middle temporal
gyrus). In a set of studies utilizing MRSI by Silveri et al., evidence for lower mI/ Cr levels
were observed in MJ-dependent young men [33,46]. While lower mI/Cr levels were
observed on a global level throughout the medial temporal lobe (MTL) region, with greater
alterations observed in predominantly WM tissue, additional regional analyses revealed that
lower mI/Cr levels were specific to the left thalamus [33,46], Significant correlations were
also observed, with mI levels predicting impulsiveness and mood symptoms in the MJ-using
group.
To the extent that early initiation of MJ use occurs during the neuromaturational period of
adolescence, three MRS studies to date have examined neurochemical alterations associated
with MJ use in adolescent populations. In work by Prescot et al., adolescent chronic MJ
users demonstrated significantly lower Glu, NAA, tCr and mI in the ACC than healthy age-
matched non-users [32]. In addition, recent work by the same group extended MRS
alterations in the same set of adolescent MJ users to include lower levels of gamma-
aminobutyric acid (GABA), also observed in the ACC [47]. In a study of polydrug using
adolescents from South Africa, adolescents who used methamphetamine (MA) + MJ
exhibited significantly lower frontal lobe NAA/tCr ratios relative to similarly aged healthy
non-users and those who used methamphetamine alone [48],
Discussion
Emerging empirical data indicate converging evidence for neurochemical alterations in MJ
users, with lower NAA being the most frequently observed alteration, apparent in six out of
the eight published studies. Lower NAA levels were observed in frontal lobe regions of
interest, including the DLPFC, ACC, inferior frontal gyrus and midfrontal GM. Thus, NAA
may be a more sensitive marker reflecting MJ neurotoxic effects on neuronal viability.
Notably, when frontal lobe regions of interest were included in the MRS study design, NAA
alterations were observed in the youngest study participants. The second most common
finding was lower mI, observed globally in MTL WM and regionally specific to the left
thalamus, in the basal ganglia and in the ACC. Given the role of mI in inflammatory
responses, observed lower mI levels are suggestive of MJ-related immunosuppression.
Importantly, when age was included as a covariate in the analysis of mI levels in participants
who were in their fourth decade of life, mI differences were no longer statistically
significant in the basal ganglia, suggesting that age is an important factor when examining
interactions between neurochemical levels and MJ use [49]. The one published study
documenting evidence of alterations in frontal lobe GABA levels in adolescent MJ users
suggests that GABAergic abnormalities may contribute to frontal dysfunctions associated
with MJ use, however, it is difficult to discern whether or not this was a focal MJ-related
alteration, as no other comparison brain regions were examined [47], Nonetheless, this is
consistent with animal models demonstrating that cannabinoids modulate the GABA system
via the CB1 receptor with some evidence that interactions between the GABA and
cannabinoid systems are more pronounced in adolescent animals likely due in part to
ongoing development of the GABA and cannabinoid systems during adolescence [50–56],
Relationships between metabolite levels, clinical and cognitive variables examined in some
of these published studies were significant, indicating that metabolite levels may be useful
predictors of altered functioning associated with MJ use. The most frequent relationships
reported with metabolite levels were with duration or frequency of MJ use: with greater
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tamounts of MJ use being associated with lower Cho, lower NAA and lower mI. Only two
published studies, which examined the same cohort of MJ-dependent young men, reported
significant correlations between impulsiveness and mood and global mI levels in MTL WM
and in the left thalamus. Low mI levels, indicative of suppression of glial function and
which may lead to alterations in neuronal function and efficiency, was associated with less
impulse control. It is plausible that greater levels of impulsiveness led to the initiation of MJ
use in the first place, necessitating the need to characterize antecedents, as well as
consequences of MJ use. None of the other MRS studies published to date reported
significant relationships between metabolite levels and behavioral data. It is possible that the
relatively small sample sizes included in each of these studies, the largest of which included
24 HIV− MJ users, precluded the ability to detect significant differences or relationships due
to a lack of statistical power [43]. Clearly brain region of interest and metabolites of interest,
along with duration of MJ use, have emerged as important factors for identifying
neurochemical correlates of MJ use.
It should also be noted that two of the published studies included MJ-users who were also
using additional substances. One study reported findings from MA + MJ adolescent users
relative to those using MA alone, thereby limiting conclusions regarding the impact of MJ
on neurochemistry, although significant correlations with MJ use were reported [48]. The
second study included recreational young adult drug users who were using ecstasy, alcohol,
MJ and cocaine, with no MJ-only group or matched non-using comparison group, again
limiting conclusions about MJ use alone [45]. Finally, the largest study published to date
included MJ users who were both HIV+ and HIV−. Given that the MJ-only group was
significantly younger than the other three groups, conclusions drawn from this study are also
limited.
There are other methodological factors that should also be considered, including variables
associated with drug consumption, co-morbid psychiatric conditions, and age and sex
differences. For instance, period of abstinence from MJ use, this was not accounted for in
any of the published studies. To the extent that washout period may play an important role in
recovery of neurometabolite concentrations, empirical investigation of length of abstinence
should be examined in future studies. Structured clinical interviews confirmed MJ
dependence in three of the eight studies, whereas the five remaining studies included heavy
users. Thus, it is important to consider the potential risk factors and effects of psychiatric
comorbidity, especially given recent reports that MJ use is associated with earlier onset of
psychosis and psychotic thinking and that lower NAA/tCr ratios in the DLPFC and
associated neuropsychological deficits have been reported in patients with schizophrenia
[57–60]. The age of the participants in the eight studies ranged from approximately 15 to 45
years, limiting comparisons across studies. However, given that the frontal cortex undergoes
the most substantial changes during adolescence, and the onset of drug use often occurs
during this period, age of testing in a very important variable to include in MRS
investigations of MJ use [61]. Indeed, drug use during the adolescent period may alter the
healthy development of the brain via neurotoxic effects of substances on neurochemistry,
with polydrug use leading to even greater neurochemical alterations during this critical
period of brain development [48]. Finally, there is a significant need for the investigation of
sex differences in neurochemistry, underscored by the inclusion of only eight females
collectively in MJ-only groups across each of the eight MRS/MRSI studies. In light of sex-
specific findings from other non-MRS studies of MJ use, as well as reports on the role of the
menstrual cycle phase and sex hormones on neurochemical metabolites identifying potential
sex differences in MJ-related alterations of brain metabolite concentrations will significantly
contribute to this growing literature [55,62,63],
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tThere are challenges associated with MRS acquisition and quantification that are necessary
to consider when interpreting MRS data. Increasing scanner field strength permits increased
MR signal, which is field strength dependent, thereby increasing overall sensitivity. Only
one published study acquired MRS data at 1.5 Tesla, whereas all other MRS data were
acquired at relatively higher field strengths of 3.0 and 4.0 Tesla. The method chosen for
spatial localization also can impact the quality of the data collected, with single voxel
spectra typically having higher resolution than spectra acquired using MRSI. An advantage
of MRSI, however, is the extraction of metabolite spectra from multiple adjacent voxels that
can be selected from various regions of interest and investigated during post-processing of
MRS data. The choice of spatial localization approach is dependent, therefore, on the a
priori hypotheses of the study. It is also important to empirically quantify tissue
contributions in the voxel or voxels of interest, as previous studies have shown that proton
metabolite concentrations vary with tissue type [64]. Another important factor to consider is
the selection of an unbiased reference standard with which to derive absolute metabolite
concentrations, rather than assuming that the usual internal references (i.e., Cr, water) are
unchanged between populations. As such, the majority of MJ studies conducted to date have
utilized either Cr or unsuppressed water as a denominator for determining metabolite ratios,
with the exception of the study by Chang and colleagues, who determined absolute
concentrations. Cr has typically been considered a relatively stable in vivo metabolite peak,
which is typically maintained at constant levels in healthy tissue, and therefore routinely
used for determining metabolite ratios. The investigation by Chang and colleagues showed
that Cr levels varied between subject populations, thereby reducing the likelihood that Cr is
an unbiased denominator. The unsuppressed peak arising from water is also routinely used
as an internal reference for calculating metabolite ratios, as used by Prescot et al. [32] group,
but also is complicated due to the need to discriminate between water in tissue versus water
in CSF, which can differ in measurement up to 10–40% [65,66]. Notably, although each of
these studies used varying acquisition methods, different field strengths, and examined a
variety of regions of interest, there remains converging evidence for an overall trend for MJ-
related disruptions in NAA and mI concentrations.
Conclusion and Future Directions
In summary, this review of the existing MRS/MRSI studies of MJ use demonstrates
evidence that smoking MJ alters brain metabolite levels, suggesting a potential neurotoxic
effect of marijuana that could be related to a reduction in neuronal viability and altered
inflammatory responses associated with chronic use. Future work is warranted to investigate
relationships of neurochemical alterations with correlates of clinical and cognitive variables
and risk-taking behaviors. Data from this limited collection of studies indicate that this is a
significantly understudied area of research, warranting additional investigations, since this
review was limited to only eight published studies utilizing MRS to investigate MJ-related
alterations in brain chemistry. First, studies should be conducted to characterize the effects
of MJ use using a prospective design that follows early onset users from initiation of use,
through the critical period of brain development, and into the early 20s, i.e., neurobiological
adulthood, when adolescent maturational changes begin to plateau [67,68]. Second, future
studies should specifically target MJ use in females, in order to address potential sex-
specific differences in the neurochemical consequences of MJ use, which could offer some
insight for tailoring individual treatment plans. Third, given that duration of MJ use has been
correlated with metabolite alterations across the majority of the available MRS studies, it
will be important to characterize and elucidate the effects of extended periods of marijuana
exposure, as well as abstinence, on proton metabolite levels and recovery in both younger
and older cohorts. Lastly, given that recent pharmacological interventions targeting the
GABA system in adults offer some promise for improved recovery from MJ dependence, a
more detailed understanding of MJ effects on this inhibitory neurotransmitter system in
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thuman subjects is needed [69,70]. Thus, there are a number of future directions for research
in this area, utilizing powerful non-invasive methods for assaying in vivo neurochemistry,
which would fill critical gaps in the existing MJ use literature.
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1H Proton
ACC anterior cingulate cortex
BA Brodmann Area
BDI Beck Depression Inventory
BG basal ganglia
BIS Barratt Impulsiveness Scale
CBV Cerebral Blood Volume
Cho choline
CON healthy control group
Cr creatine
CSF Cerebrospinal fluid
DLPFC dorsolateral prefrontal cortex
DSC Dynamic Susceptibility Contrast
DTI Diffusion Tensor Imaging
F female
fMRI Functional magnetic resonance imaging
FWM frontal white matter
GABA gamma-aminobutyric acid
Gin Glutamine
Glu glutamate
Glx Glutamine/Glutamate/GABA complex
GM gray matter
H20 normalized water signal
HC hippocampus
K-SADS Kiddie-Schedule for Affective Disorders and Schizophrenia
l left
MA methamphetamine
mI myo-Inositol
Sneider et al. Page 7
J Addict Res Ther. Author manuscript; available in PMC 2014 February 27.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tMJ marijuana
MRI Magnetic Resonance Imaging
MRS magnetic resonance spectroscopy
MRSI magnetic resonance spectroscopic imaging
MTL medial temporal lobe
NAA N-acetyl-aspartate
NU non-using
Occ occipital
Par parietal
PCC posterior cingulate cortex
PCr phosphocreatine
POC parieto-occipital cortex
POMS Profile of Mood States
r right
rec recreational
SV single voxel
t total
T Tesla
TC temporal cortex
Thai thalamus
THC Δ9 tetrahydrocannabinol
VTA ventral tegmental area
WM white matter
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tFigure 1.
Sample Single Voxel Thalamic 1H Spectrum. Axial anatomical image illustrating the
placement of a single voxel (2 × 2 × 3cm) in the right thalamus of a healthy subject acquired
at 4.0 Tesla using 2D-JPRESS, and the associated 1H spectrum (below). Abbreviations: tCr
(Cr + PCr), total creatine; Glx, glutamine/glutamine/GABA complex; ml, myo-inositol;
tCho, total choline; Glu, glutamate; NAA, N-acetylaspartate.
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